WO2015119235A1 - 結晶性l-カルノシン亜鉛錯体を含有する精製体の製造方法 - Google Patents
結晶性l-カルノシン亜鉛錯体を含有する精製体の製造方法 Download PDFInfo
- Publication number
- WO2015119235A1 WO2015119235A1 PCT/JP2015/053354 JP2015053354W WO2015119235A1 WO 2015119235 A1 WO2015119235 A1 WO 2015119235A1 JP 2015053354 W JP2015053354 W JP 2015053354W WO 2015119235 A1 WO2015119235 A1 WO 2015119235A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- carnosine
- alkali metal
- zinc
- mass
- alcohol
- Prior art date
Links
- MORUQNQGRSLTCD-FJXQXJEOSA-N (2s)-2-(3-aminopropanoylamino)-3-(1h-imidazol-5-yl)propanoic acid;zinc Chemical compound [Zn].NCCC(=O)N[C@H](C(O)=O)CC1=CNC=N1 MORUQNQGRSLTCD-FJXQXJEOSA-N 0.000 title claims abstract description 63
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 24
- 239000013014 purified material Substances 0.000 title abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 79
- 229910052783 alkali metal Inorganic materials 0.000 claims abstract description 66
- -1 alkali metal salt Chemical class 0.000 claims abstract description 66
- 239000007788 liquid Substances 0.000 claims abstract description 64
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 81
- 239000012043 crude product Substances 0.000 claims description 56
- 108010087806 Carnosine Proteins 0.000 claims description 33
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 claims description 33
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 claims description 33
- 229910052725 zinc Inorganic materials 0.000 claims description 31
- 239000011701 zinc Substances 0.000 claims description 31
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 30
- 238000001914 filtration Methods 0.000 claims description 21
- 239000007787 solid Substances 0.000 claims description 19
- 239000012264 purified product Substances 0.000 claims description 17
- 125000004432 carbon atom Chemical group C* 0.000 claims description 15
- 150000001339 alkali metal compounds Chemical class 0.000 claims description 8
- 150000003752 zinc compounds Chemical class 0.000 claims description 7
- 239000013058 crude material Substances 0.000 abstract description 11
- 238000000034 method Methods 0.000 description 55
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 37
- 238000005406 washing Methods 0.000 description 25
- 239000000047 product Substances 0.000 description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 238000004140 cleaning Methods 0.000 description 14
- 239000006185 dispersion Substances 0.000 description 13
- 239000002994 raw material Substances 0.000 description 13
- 238000001035 drying Methods 0.000 description 10
- 238000000926 separation method Methods 0.000 description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 8
- 239000013078 crystal Substances 0.000 description 8
- 239000012535 impurity Substances 0.000 description 8
- 239000013557 residual solvent Substances 0.000 description 8
- 239000001632 sodium acetate Substances 0.000 description 8
- 235000017281 sodium acetate Nutrition 0.000 description 8
- 238000003756 stirring Methods 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 108700035912 polaprezinc Proteins 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 150000003751 zinc Chemical class 0.000 description 4
- 239000004246 zinc acetate Substances 0.000 description 4
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 150000001340 alkali metals Chemical class 0.000 description 2
- 230000000767 anti-ulcer Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000013522 chelant Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- ONDPHDOFVYQSGI-UHFFFAOYSA-N zinc nitrate Chemical compound [Zn+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ONDPHDOFVYQSGI-UHFFFAOYSA-N 0.000 description 2
- IUWLTSZHVYHOHY-FJXQXJEOSA-L zinc;(2s)-2-(3-azanidylpropanoylazanidyl)-3-(1h-imidazol-5-yl)propanoate Chemical compound [Zn+2].[NH-]CCC(=O)[N-][C@H](C([O-])=O)CC1=CN=CN1 IUWLTSZHVYHOHY-FJXQXJEOSA-L 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- WZIMSXIXZTUBSO-UHFFFAOYSA-N 2-[[bis(carboxymethyl)amino]methyl-(carboxymethyl)amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)CN(CC(O)=O)CC(O)=O WZIMSXIXZTUBSO-UHFFFAOYSA-N 0.000 description 1
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 229940044199 carnosine Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- WATYAKBWIQTPDE-UHFFFAOYSA-N pentane-2,4-dione;zinc Chemical compound [Zn].CC(=O)CC(C)=O WATYAKBWIQTPDE-UHFFFAOYSA-N 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011085 pressure filtration Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- YZYKBQUWMPUVEN-UHFFFAOYSA-N zafuleptine Chemical compound OC(=O)CCCCCC(C(C)C)NCC1=CC=C(F)C=C1 YZYKBQUWMPUVEN-UHFFFAOYSA-N 0.000 description 1
- UGZADUVQMDAIAO-UHFFFAOYSA-L zinc hydroxide Chemical compound [OH-].[OH-].[Zn+2] UGZADUVQMDAIAO-UHFFFAOYSA-L 0.000 description 1
- 229940007718 zinc hydroxide Drugs 0.000 description 1
- 229910021511 zinc hydroxide Inorganic materials 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- RXBXBWBHKPGHIB-UHFFFAOYSA-L zinc;diperchlorate Chemical compound [Zn+2].[O-]Cl(=O)(=O)=O.[O-]Cl(=O)(=O)=O RXBXBWBHKPGHIB-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
- C07F3/06—Zinc compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Definitions
- the present invention relates to a method for efficiently producing a purified product in which the amount of alkali metal salt contained in a crude product containing a crystalline L-carnosine zinc complex and an alkali metal salt is reduced.
- the L-carnosine zinc complex has been conventionally used as a therapeutic agent for gastric ulcer, and it is known that a crystalline complex and an amorphous complex exist as solid forms.
- Amorphous L-carnosine zinc complex is a chelate mixture in which various chelates are mixed, so it has poor crystallinity and is difficult to purify, and the content ratio of zinc and L-carnosine should be constant. Is difficult to manufacture and use industrially.
- the crystalline L-carnosine zinc complex is represented by the following formula (1), and the molar ratio of zinc to L-carnosine is almost 1: 1 and is a constant complex. . Furthermore, since the crystalline L-carnosine zinc complex exhibits a stronger anti-ulcer action than the amorphous state complex, crystalline L-carnosine zinc complexes are mainly used for pharmaceuticals.
- n an integer.
- a zinc salt such as zinc acetate is added to L-carnosine represented by the following formula (2) in the presence of an alkali metal compound such as sodium hydroxide.
- an alkali metal compound such as sodium hydroxide.
- the crystalline L-carnosine zinc complex produced by the above method usually has an alkali metal salt produced as a by-product when the complex is formed between L-carnosine and a zinc salt.
- This is a peritectic incorporated by 10% by mass or more per 100% by mass.
- the alkali metal salt taken into the peritectic crystal differs depending on the type of alkali metal compound and zinc salt used in the reaction. For example, when zinc acetate is used as the zinc salt and sodium hydroxide is used as the alkali metal compound, Become.
- Patent Document 1 discloses a method of washing the L-carnosine zinc complex crystals separated by filtration with water.
- Patent Document 2 discloses a method of removing the alkali metal salt by bringing it into contact with water having a high solubility of the alkali metal salt. Specifically, the crude product is treated with a specific amount of water. In which the alkali metal salt is selectively dissolved and removed by stirring for a certain time at a specific temperature.
- the alkali metal salt is dissolved and contained in the moisture contained in the wet body, when it is dried as it is, the crystalline L-carnosine zinc complex finally obtained still has a considerable amount of alkali metal. Since the salt remains, the alkali metal salt cannot be reduced sufficiently depending on the amount of alkali metal salt contained in the crude body and the amount of water used for washing. It was found that it was necessary to further perform operations such as washing with water on the body.
- the obtained wet body contains a large amount of water, it is necessary to dry for a long time under severe conditions such as high temperature and reduced pressure in order to reduce the amount of water in the wet body. It was a big problem to implement.
- the wet body of crystalline L-carnosine zinc complex obtained by the method described in Patent Document 2 contains 50% by mass or more of water, and in order to obtain a dry body from the wet body, It was necessary to dry for a long time. Furthermore, the dried product thus obtained is hard and agglomerated, and it takes a long time to pulverize, and it is difficult to control the particle size after pulverization.
- the present inventor has intensively studied and, as described above, has found that the problem in the case of using water having high alkali metal salt solubility is filterability.
- This problem of filterability is considered to be due to the dispersion of the crystalline L-carnosine zinc complex dispersed in water in addition to the properties of water that is difficult to filter.
- the alkali metal salt may not be reduced, so we do not consider using other cleaning media for cleaning, Since the present inventor found out that the problem in using water is the filterability, the inventors proceeded with the study of the cleaning medium.
- the solubility of the alkali metal salt is lower than that of water, but it has been found that the above problem can be solved by using an alcohol with improved operability, and the present invention has been completed.
- the present invention includes a step A in which a crude product containing a crystalline L-carnosine zinc complex and an alkali metal salt is contacted with a liquid containing an alcohol having 1 to 3 carbon atoms.
- This is a method for producing a purified product that is reduced and contains a crystalline L-carnosine zinc complex.
- the content of the alkali metal salt in the purified product is preferably 0.5% by mass or less with respect to 100% by mass of the solid content of the purified product.
- the crude body is preferably a crude body obtained by reacting L-carnosine, a zinc compound and an alkali metal compound in the presence of an alcohol, and the content of the alkali metal salt in the crude body is It is preferable that it is 10 mass% or more with respect to 100 mass% of solid content.
- the alcohol having 1 to 3 carbon atoms is preferably methanol, and the step A preferably includes at least one of the following step A1 or step A2.
- Step A1 Step of dispersing the crude body in a liquid containing an alcohol having 1 to 3 carbon atoms
- Step A2 Step of bringing a liquid containing an alcohol having 1 to 3 carbon atoms into contact with the crude body in the filtering means
- the crude product by bringing a crude product containing a crystalline L-carnosine zinc complex into contact with a liquid containing an alcohol, the crude product is contained in the crude product without changing the content ratio of zinc and L-carnosine.
- the alkali metal salt to be reduced can be reduced.
- a crystalline L-carnosine zinc complex having good filterability during washing and good crystallinity can be easily obtained.
- a crystalline L-carnosine zinc complex with a reduced amount of liquid containing alcohol used for washing can be obtained efficiently.
- the crystalline L-carnosine zinc complex obtained by washing with a liquid containing alcohol becomes a complex (ie, small particles) that is bulky and has a large specific surface area compared to the complex obtained by washing with water. It is considered that the contact efficiency between the liquid containing alcohol and the crystalline L-carnosine zinc complex is increased, and the alkali metal salt is easily removed. For this reason, alcohol is considered to be able to reduce the alkali metal salt efficiently, although the solubility of the alkali metal salt is lower than that of water. In addition, a bulky complex having a large specific surface area is usually considered to have poor filterability.
- the reason is that the dispersion state of the crystalline L-carnosine zinc complex is different between the case of using a liquid containing alcohol and the case of using water, and that the liquid containing alcohol can be easily removed.
- a dried product can be easily obtained, and the dried product can be easily pulverized.
- the present invention includes a step A in which a crude product containing a crystalline L-carnosine zinc complex and an alkali metal salt (hereinafter also simply referred to as “crude product”) is contacted with a liquid containing an alcohol having 1 to 3 carbon atoms.
- This is a method for producing a purified product in which the content of the alkali metal salt is reduced and the crystalline L-carnosine zinc complex is contained.
- the crude product is not particularly limited as long as it contains an alkali metal salt and a crystalline L-carnosine zinc complex, and may be a dry product, and a solvent used in the production of the crude product (hereinafter referred to as “residual solvent”). May be a wet body in which the residual is left.
- residual solvent a solvent used in the production of the crude product
- the amount of the alkali metal salt contained in the crude product to be purified is not particularly limited, but the method of the present invention is such that the crude product is an alkali metal based on 100% by mass of the solid content of the crude product. When the salt is contained in an amount of 10% by mass or more, an excellent effect is exhibited.
- the alkali metal salt is 10% with respect to 100% by mass of the solid content of the crude body.
- the effect which was excellent by making the rough object contained in the mass% or more into washing object is exhibited.
- the solid content of the crude product contains 10 to 30% by mass of an alkali metal salt and 70 to 90% by mass of a crystalline L-carnosine zinc complex.
- content of the alkali metal salt in the said rough body is less than 10 mass% with respect to 100 mass% of solid content of this rough body, the outstanding effect is exhibited.
- the crude product has an alkali metal salt of more than 0.1% by mass to 30% by mass and a crystalline L-carnosine zinc complex of 70% by mass or more in the solid content. What is contained in an amount of less than 99.9% by mass is preferable. Further, the alkali metal salt exceeds 0.3% by mass and is 30% by mass or less, and the crystalline L-carnosine zinc complex is 70% by mass or more and 99.7% by mass. Those contained in less than amounts are preferred.
- Patent Document 1 that is, zinc of a carboxylic acid such as L-carnosine, zinc halide, zinc sulfate, zinc nitrate, zinc perchlorate, zinc acetate in an anhydrous or hydrous polar solvent. It can be produced by a method in which a zinc compound such as a salt or zinc acetylacetone and an alkali metal compound such as lithium hydroxide, potassium hydroxide, sodium hydroxide, potassium alcoholate or sodium alcoholate are reacted.
- a carboxylic acid such as L-carnosine, zinc halide, zinc sulfate, zinc nitrate, zinc perchlorate, zinc acetate in an anhydrous or hydrous polar solvent.
- a zinc compound such as a salt or zinc acetylacetone and an alkali metal compound such as lithium hydroxide, potassium hydroxide, sodium hydroxide, potassium alcoholate or sodium alcoholate are reacted.
- the crude product obtained by the reaction contains an alkali metal salt by-produced in the reaction as an impurity, and the kind of the alkali metal salt is determined by the kind of the zinc compound and alkali metal compound used in the reaction. For example, when zinc acetate is used as the zinc compound and sodium hydroxide is used as the alkali metal compound, sodium acetate is obtained.
- the crude product obtained by the above method usually contains a solid content and a residual solvent, and the solid content has a ratio of zinc to L-carnosine of 95 to 95 mol of L-carnosine. 105, preferably 99 to 101 mol of crystalline L-carnosine zinc complex and 10% by mass or more of alkali metal salt are contained.
- the upper limit of the alkali metal salt is not particularly limited but is 40% by mass.
- the method for producing the crude product is not limited to the above-described method, and any method may be used as long as a crude product containing at least one crystalline L-carnosine zinc complex and an alkali metal salt can be obtained.
- the crude product obtained by this method usually contains a crystalline L-carnosine zinc complex, an alkali metal salt, and an alcohol.
- the method according to the present invention is a method not conventionally performed by those skilled in the art to further contact alcohol with the crude product containing alcohol, and has the above-described remarkable effects.
- the crude body is not particularly limited, and those obtained by the above method and the like can be used as they are, but known purification methods such as a method of washing with water (Patent Document 1), water It is also possible to use a material in which impurities such as alkali metal salts are reduced by refining at least once by the method of reslurry with (Patent Document 2).
- the rough body may be a powder, a lump, a dry body in which these are mixed, or a wet body containing a residual solvent.
- the wet body may be a wet body containing an alcohol having 1 to 3 carbon atoms, and other solvents and / or water may remain within the range not affecting the present invention. Most preferably it is free of solvent and water.
- the liquid containing an alcohol having 1 to 3 carbon atoms (hereinafter also referred to as “alcohol liquid”) used as a cleaning medium in the present invention is not particularly limited, and includes a liquid containing methanol, ethanol, 2-propanol or the like. be able to. Only one kind of these alcohols may be used, or a plurality of kinds of alcohols may be appropriately mixed and used. In the present invention, it is particularly preferable to use methanol alone, and by using methanol alone, the filterability becomes better, and further, the effect of removing the alkali metal salt is high, so that crystals with higher purity can be obtained. Can be obtained efficiently.
- the alcohol liquid examples include liquids containing the alcohol and other components other than the alcohol, for example, water, alcohols, ethers, esters, ketones, amines, nitriles, or sulfoxides.
- the other component is preferably water.
- the alcohol liquid is preferably a liquid that does not substantially contain the other components, particularly water.
- the content of the alcohol having 1 to 3 carbon atoms in the alcohol liquid is preferably 50 to 100% by mass, more preferably 60 to 100% by mass, still more preferably 80 to 100% by mass, and particularly preferably. Is approximately 100% by mass (other components are 0.05% by mass or less).
- the method for bringing the crude product into contact with the alcohol liquid is not particularly limited, but specific methods include a method of dispersing the crude product in the alcohol liquid (hereinafter also referred to as “reslurry”), and Examples include a method (hereinafter also referred to as “rinse cleaning”) in which an alcohol liquid is brought into contact with the rough body in the filtering means, and it is preferable to use at least one of these methods.
- reslurry a method of dispersing the crude product in the alcohol liquid
- rinse cleaning a method in which an alcohol liquid is brought into contact with the rough body in the filtering means
- the reslurry is not particularly limited, but is preferably a method of stirring a dispersion obtained by dispersing the rough body in an alcohol liquid, and 0.01 parts by weight or more with respect to 1 part by weight of the solid content of the rough body. It is preferable that the dispersion obtained by dispersing the crude product in the alcohol liquid is stirred for 0.5 hours or more while maintaining the temperature of the dispersion at 1 to 30 ° C.
- the method for dispersing the crude product in an alcohol liquid is not particularly limited, and specific examples include a method in which the crude product and the alcohol liquid are mixed and stirred. At this time, the crystalline L-carnosine zinc complex is hardly dissolved in the alcohol liquid and becomes a suspended dispersion. In this method, it is preferable to stir for 0.5 hour or longer while maintaining the temperature of the dispersion at 1 to 30 ° C. in the state of the dispersion. By stirring under the conditions, an alkali metal salt as an impurity is sufficiently eluted into the system, and a crystalline L-carnosine zinc complex with a reduced content of the alkali metal salt can be obtained. In view of the removal effect and operability of the alkali metal salt, the temperature of the dispersion is more preferably 5 to 30 ° C., and the stirring time is more preferably 1 to 30 hours.
- the amount of the alcohol liquid used in the method is preferably 0.01 parts by mass or more, more preferably 0.05 parts by mass or more, based on 1 part by mass of the solid content of the crude body. It is particularly preferably 1 part by mass or more.
- the amount of the alcohol liquid is sufficiently eluted into the system.
- it does not specifically limit about an upper limit, when operativity and efficiency are considered, it is preferable that it is 100 mass parts or less, and it is more preferable that it is 90 mass parts or less.
- the crude solid content means the mass of a dried product when a crude wet product (undried product) to be purified is dried in air at 150 ° C. for 3 hours. means.
- the mass of the dried product does not necessarily coincide with the “total mass of the L-carnosine zinc complex and impurity salt” contained in the crude product, but is considered to be almost equivalent.
- the content of the alkali metal salt in the solid content of the crude product used in the above method is 10% by mass or more.
- the content of the alkali metal salt is reduced depending on the amount of alcohol liquid used. It is 0.5 mass% or less with respect to 100 mass% of solid content, Preferably it can be 0.3 mass% or less.
- the method of making the said rough body and alcohol liquid contact is the method of making alcohol liquid contact the said rough body in a filtration means.
- filtration means examples include pressure filtration and vacuum filtration devices, centrifuges, and the like, and at least alkali metal salt and alcohol liquid can be discharged from the inside of the filtration means through a filter such as filter paper.
- Means apparatus may be mentioned.
- the method of bringing the alcohol liquid into contact with the rough body in the filtering means is not particularly limited, and specific examples include a method of adding the alcohol liquid to the rough body in the filter or the centrifuge. At this time, it is preferable that the entire coarse body is in contact with the alcohol liquid. Further, although depending on the amount of the filtering means and the amount of alcohol liquid used, it is more preferable that the alcohol liquid is added to the rough body in the filtering means and then mixed by stirring to obtain a uniform mixture. Therefore, when the coarse body and the alcohol liquid are brought into contact with each other, the alcohol liquid or the like may be discharged to the outside from the inside of the filtering means. It is good also as a state which is not discharged
- the amount of the alcohol liquid used in the method is not particularly limited, but is preferably 0.001 part by mass or more and more preferably 0.01 part by mass or more with respect to 1 part by mass of the solid content of the crude body. preferable.
- Solid-liquid separation the product obtained by bringing the crude product into contact with the alcohol liquid, for example, the dispersion obtained by the reslurry or the mixture in the filtering means obtained by the rinse washing is subjected to solid-liquid separation.
- the filterability at the time is good.
- solid-liquid separation using a known method such as filtration or centrifugation, the content of the alkali metal salt is reduced, and the crystalline L-carnosine zinc complex does not contain an excessive amount of residual solvent or washing medium.
- a wet body can be obtained efficiently in a short time. This wet body is a purified body in the present invention, and a dried body obtained by drying the wet body is also a purified body in the present invention.
- the filterability is poor and a wet body containing an excessive amount of residual solvent or washing medium is obtained, it is necessary to perform operations such as washing several times in order to remove the alkali metal salt.
- the present invention is also very efficient in that a simple operation can be completed at a minimum.
- the obtained wet body of crystalline L-carnosine zinc complex is dried by natural drying, blast drying, vacuum drying, or the like, if necessary, so that the crystalline L- A carnosine zinc complex can be easily obtained in a short time. That is, according to the present invention, it can be said that a wet body having excellent drying properties can be obtained.
- the residual solvent or cleaning medium content is preferably 5% by mass or less by drying in a normal or reduced pressure atmosphere at a temperature of 30 to 90 ° C. for 1 to 100 hours, preferably 1 to 50 hours. Can easily obtain a crystalline L-carnosine zinc complex of 3% by mass or less.
- the crystalline L-carnosine zinc complex thus obtained has a reduced alkali metal salt content, and the molar ratio of zinc to L-carnosine ⁇ zinc (mol) / L-carnosine (mol) ⁇ Is substantially the same as the molar ratio of zinc to L-carnosine in the complex in the crude body.
- the molar ratio after purification is within ⁇ 1%, preferably within ⁇ 0.8% of the molar ratio before purification, in consideration of the accuracy of the analyzer, Specifically, the molar ratio of zinc to L-carnosine in the obtained crystalline L-carnosine zinc complex (purified product) relative to the molar ratio of zinc to L-carnosine in the crude product (L The molar ratio of zinc to carnosine / molar ratio of zinc to L-carnosine in the crude body) is preferably 0.90 to 1.10, more preferably 0.95 to 1.05, still more preferably 0.8. 99 to 1.01.
- the L-carnosine zinc complex is hardly decomposed during the purification, or even if the decomposition occurs, the decomposition product, particularly a zinc compound such as zinc hydroxide, remains in the purified product as an impurity. Means difficult.
- the alkali metal salt content is 0.5 mass% or less, preferably 0.3 mass% or less, and the zinc content is 21.46 to 23.72 mass%, preferably Is 22.35 to 22.81% by mass
- the ratio of zinc to L-carnosine is 95 to 105, preferably 99 to 101 mol of zinc with respect to 100 mol of L-carnosine
- the residual solvent and a crystalline L-carnosine zinc complex having a cleaning medium content of 5% by mass or less, preferably 3% by mass or less has good filterability during solid-liquid separation and good drying efficiency. be able to.
- the crystalline L-carnosine zinc complex obtained in the present invention does not usually contain impurities at a level that is problematic for pharmaceuticals and the like.
- the method of the present invention can be performed a plurality of times depending on the purpose, and can be performed by combining the reslurry operation and the rinse cleaning operation.
- the rinse washing operation can be performed on a wet body obtained by solid-liquid separation of the dispersion obtained by performing the reslurry operation by filtration or centrifugation.
- the rinse washing operation can be performed on a wet body obtained by solid-liquid separation from a reaction solution obtained by reacting L-carnosine and a zinc compound by the method described in Patent Document 1.
- a portion (obtained amount 2060 g) of the obtained wet body (hereinafter also referred to as “raw material crude material”) was taken out and analyzed, and the breakdown was as follows: sodium acetate 100 g, crystalline L-carnosine zinc complex 520 g, and methanol 1440 g. there were. The results are summarized in Table 1.
- the remaining sodium acetate was analyzed by 1 H-NMR, and the zinc was determined by chelate titration with 0.01 M ethylenediaminetetraacetic acid disodium solution.
- the content ratio of zinc in the carnosine zinc complex, and the molar ratio is the molar ratio of zinc and L-carnosine in the crystalline L-carnosine zinc complex. It was confirmed by X-ray diffraction that the obtained crystal was a crystalline L-carnosine zinc complex.
- the mass of the crystalline L-carnosine zinc complex is determined from the difference between the mass of the obtained crude or dried product and the mass of other components (residual volatiles such as residual sodium acetate and residual methanol) other than the complex. be able to.
- Example 1 (rinse cleaning) 206 g of the raw material crude material after filtration obtained in Production Example 1 was washed with 100 ml of methanol while being on the Nutsche to obtain 92.2 g of a first crude material.
- first coarse body the coarse body obtained by reslurry or rinsing the raw material coarse body
- second coarse body the coarse body obtained by reslurry or rinsing the first coarse body
- the obtained first crude product is a purified product in the present invention
- the second crude product is also a purified product in the present invention.
- the filterability at the time of obtaining the first crude product was good, and the distillate filtrate disappeared in 5 minutes, and the filtration operation was completed.
- the breakdown of the obtained first crude product was 0.2 g of sodium acetate, 52 g of crystalline L-carnosine zinc complex, and 40 g of methanol.
- zinc (mol): L-carnosine (mol) in the complex contained in the first crude body 1.000: 1. It turns out that it is 000.
- the obtained first crude product was air-dried at 80 ° C. for 3 hours to obtain 52.2 g of a dried white solid (52 g of crystalline L-carnosine zinc complex, 0.2 g of sodium acetate).
- the drying is performed until the residual amount of water and alcohol is 3% or less, and the obtained product after drying is also referred to as a dried product.
- Table 2 The results are summarized in Table 2.
- Example 2 (reslurry) The raw material coarse body 206g obtained in Production Example 1 was charged into a 1000 ml four-necked flask, and 800 ml of methanol was added thereto. Thereafter, the mixture was stirred at a constant temperature of 25 ° C. for 2 hours and then filtered through a Nutsche to obtain 89.1 g of a first crude product. The filterability when obtaining the first crude product was good, and the distillate filtrate disappeared in 10 minutes, and the filtration operation was completed. The obtained first crude product was air-dried at 80 ° C. for 3 hours to obtain a dried product (52 g of crystalline L-carnosine zinc complex, 0.1 g of sodium acetate). The results are shown in Table 3.
- Example 3 (reslurry, rinse washing) 89.1 g of the first crude product obtained in the same manner as in Example 2 was washed with 100 ml of methanol on Nutsche to obtain 86.1 g of the second crude product. The filterability was good, and the distillate filtrate disappeared in 5 minutes, and the filtration operation was completed. The obtained second crude product was air-dried at 80 ° C. for 3 hours to obtain a dried product (crystalline L-carnosine zinc complex 52 g, sodium acetate 0.05 g). The results are shown in Table 4.
- Example 4 (rinse cleaning) The same procedure as in Example 1 was carried out except that the medium for rinsing and washing the crude raw material was changed from methanol to ethanol. The results are shown in Table 5.
- the volatile matter contained in the first or second crude body is also referred to as residual volatile matter.
- Example 5 (rinse cleaning) The same procedure as in Example 1 was performed except that the medium for rinsing and washing the raw material crude material was changed from methanol to isopropyl alcohol (hereinafter also referred to as “IPA”). The results are shown in Table 5.
- IPA isopropyl alcohol
- Example 7 (reslurry) The same procedure as in Example 2 was performed except that the medium added to the raw material crude material was changed from methanol to ethanol. The results are shown in Table 6.
- Example 8 (reslurry) The same procedure as in Example 2 was performed except that the medium added to the raw material crude material was changed from methanol to IPA. The results are shown in Table 6.
- Comparative Example 1 The same procedure as in Example 1 was performed except that the medium for rinsing and washing the raw material crude material was changed from methanol to water. The filterability at this time was poor, requiring 5 hours. The results are shown in Table 7.
- Comparative Example 2 The same procedure as in Example 2 was performed except that the medium added to the raw material crude material was changed from methanol to water. The filterability at this time was poor, and 10 hours were required. Moreover, since the obtained 1st rough body was not dried by the air drying at 80 degreeC, it dried under reduced pressure at 80 degreeC for 24 hours. The results are shown in Table 8.
- Example 10 It processed like Example 2 except having used 141.1g of 1st coarse bodies (wet body) obtained by comparative example 2 instead of 206g of raw material coarse bodies. The obtained second crude product was air-dried at 80 ° C. for 4 hours. In Example 10, the first rough body obtained in Comparative Example 2 is the rough body in the present invention. The results are shown in Table 9.
- the liquid containing alcohol particularly alcohol and further methanol
- the washing medium for the crystalline L-carnosine zinc complex obtained by synthesis so that the alkali metal salt as an impurity can be obtained.
- solid-liquid separation operations such as filtration and centrifugation could be performed simply and in a short time.
- a dry product can be obtained from the wet product after solid-liquid separation in a short time by a simple method.
- the obtained crystalline L-carnosine zinc complex had a constant molar ratio of zinc to L-carnosine of approximately 1: 1, and this molar ratio did not change substantially before and after washing.
- the dried product obtained in Comparative Example 2 was hard and agglomerated. To use this dried product, it was necessary to grind it in a mortar or the like, but the dried product obtained in Examples 1 to 10 was used. The body could be pulverized more easily than the dried body of Comparative Example 2, and the particle size was easy to control. This is presumably because a dried product having a weak cohesive force (easy to grind) was obtained by using alcohol. From the above, the production method according to the present invention is an industrially advantageous method as a method for obtaining an L-carnosine zinc complex that is suitably used for pharmaceuticals having a stronger antiulcer action.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
特許文献1には、濾別したL-カルノシン亜鉛錯体の結晶を水を用いて洗浄する方法が開示されているが、当該アルカリ金属塩は前記粗体の結晶内に封じ込められているため、水を用いた洗浄では結晶内に封じ込められているアルカリ金属塩を十分に除去できない。一方、特許文献2には、当該アルカリ金属塩を除去する方法として、アルカリ金属塩の溶解度が高い水と接触させる方法が開示されており、具体的には、前記粗体を、特定量の水に分散させ、特定の温度にて一定時間撹拌することにより、当該アルカリ金属塩を選択的に溶解させて除去する方法が記載されている。
通常であれば、アルカリ金属塩の溶解度が高い水を使用した場合であっても、アルカリ金属塩が低減できない場合があるため、洗浄に他の洗浄媒体を使用する検討は行わないと考えるが、本発明者は、水を使用した際の問題が濾過性にあることを突き止めたため、洗浄媒体の検討を進めた。その結果、アルカリ金属塩の溶解度は水よりも低いが、操作性の向上するアルコールを使用することにより、上記課題を解決できることを見出し、本発明を完成するに至った。
前記精製体中におけるL-カルノシンに対する亜鉛のモル比/前記粗体中におけるL-カルノシンに対する亜鉛のモル比=0.90~1.10 ・・・(I)
工程A1:前記粗体を炭素数1~3のアルコールを含む液体に分散させる工程
工程A2:濾過手段内の前記粗体に炭素数1~3のアルコールを含む液体を接触させる工程
前記粗体は、アルカリ金属塩と結晶性L-カルノシン亜鉛錯体とを含めば特に制限されず、乾燥体であってもよく、該粗体の製造の際に用いる溶媒(以下「残留溶媒」ともいう。)が残存した湿体であってもよい。本発明において、精製の対象となる当該粗体に含まれるアルカリ金属塩の量は特に限定されないが、本発明の方法は、前記粗体が、当該粗体の固形分100質量%に対しアルカリ金属塩を10質量%以上含む場合により優れた効果を発揮するものであり、特に、下記に詳述するリスラリー方法を採用する場合には、アルカリ金属塩が粗体の固形分100質量%に対し10質量%以上含まれる粗体を洗浄対象とすることにより優れた効果を発揮する。なお、通常の工業的生産を考慮すると、前記粗体の固形分には、アルカリ金属塩10~30質量%及び結晶性L-カルノシン亜鉛錯体70~90質量%が含まれることが好ましい。ただし、本発明においては、前記粗体におけるアルカリ金属塩の含有量が該粗体の固形分100質量%に対し10質量%未満であっても優れた効果を発揮する。そのため、特に制限されるわけではないが、当該粗体は、その固形分中に、アルカリ金属塩が0.1質量%を超え30質量%以下、結晶性L-カルノシン亜鉛錯体が70質量%以上99.9質量%未満の量で含まれるものが好ましく、さらに、アルカリ金属塩が0.3質量%を超え30質量%以下、結晶性L-カルノシン亜鉛錯体が70質量%以上99.7質量%未満の量で含まれるものが好ましい。
本発明において洗浄媒体として使用される炭素数1~3のアルコールを含む液体(以下「アルコール液体」ともいう。)としては、特に制限されず、メタノール、エタノール、2-プロパノール等を含む液体を挙げることができる。これらのアルコールは、一種類だけを用いてもよく、複数種類を適宜混合して用いてもよい。本発明では、特にメタノールを単独で使用することが好ましく、メタノールを単独で使用することによって、より濾過性が良好になり、さらに、アルカリ金属塩の除去効果が高いことからより高純度の結晶を効率的に得ることができる。
前記リスラリーとしては、特に限定されないが、前記粗体をアルコール液体に分散させた分散液を撹拌する方法であることが好ましく、前記粗体の固形分1質量部に対して0.01質量部以上のアルコール液体に前記粗体を分散させた分散液を、分散液の温度を1~30℃に維持しながら0.5時間以上撹拌する方法であることが好ましい。
本発明では、前記粗体とアルコール液体とを接触させる方法が、濾過手段内の前記粗体にアルコール液体を接触させる方法であることが好ましい。
本発明において、前記粗体とアルコール液体とを接触させて得られたもの、例えば、前記リスラリーで得られた分散液や、前記リンス洗浄で得られた濾過手段内の混合物は、固液分離する際の濾過性が良い。また、これを濾過や遠心分離等公知の方法で固液分離することによって、アルカリ金属塩の含有量が低減され、過剰量の残留溶媒や洗浄媒体を含まない、結晶性L-カルノシン亜鉛錯体の湿体を短時間で効率的に得ることができる。この湿体が、本発明における精製体であり、該湿体を乾燥させた乾燥体も本発明における精製体である。
濾過性が悪く、残留溶媒や洗浄媒体を過剰に含む湿体が得られる場合には、アルカリ金属塩を除去するために洗浄等の操作を複数回行なう必要があるところ、本発明では、そのような操作を最低限で済ませることができる点においても本発明は非常に効率的である。
撹拌装置と温度計を備えた10000mlの4つ口フラスコにメタノール3730ml、水酸化ナトリウム124g(3.1mol)を加え、撹拌溶解した。溶解後、5℃以下まで冷却し、L-カルノシン350g(1.5mol)を加えて溶解した。その後、酢酸亜鉛・2水和物340g(1.55mol)をメタノール5000mlに溶解した溶液を30分かけて滴下し、2時間熟成した。一夜放置後、結晶をヌッチェにて濾過した。得られた湿体(以下「原料粗体」ともいう。)の一部(取得量2060g)を取り出し分析したところ、その内訳は、酢酸ナトリウム100g、結晶性L-カルノシン亜鉛錯体520g、メタノール1440gであった。結果を表1にまとめる。
製造例1で得られた濾過後の原料粗体206gをヌッチェ上にある状態で、メタノール100mlで洗浄し、第一粗体92.2gを得た。以下、原料粗体をリスラリー又はリンス洗浄した粗体を「第一粗体」、第一粗体をリスラリー又はリンス洗浄した粗体を「第二粗体」ともいう。ここで、得られた第一粗体が、本発明における精製体であり、また、第一粗体から第二粗体を得る場合には、該第二粗体が本発明における精製体でもある。
製造例1で得られた原料粗体206gを1000mlの4つ口フラスコに仕込み、そこにメタノール800mlを添加した。その後、25℃一定で2時間撹拌後、ヌッチェで濾過し、第一粗体89.1gを得た。該第一粗体を得る際の濾過性は良好で、10分で留出濾液がなくなり、濾過作業が終了した。得られた第一粗体を80℃で3時間風乾し、乾燥体(結晶性L-カルノシン亜鉛錯体52g、酢酸ナトリウム0.1g)を得た。結果を表3に示す。
実施例2と同様にして得られた第一粗体89.1gをヌッチェ上にてメタノール100mlで洗浄し、第二粗体86.1gを得た。濾過性は良好で5分で留出濾液がなくなり、濾過作業が終了した。得られた第二粗体を80℃で3時間風乾し、乾燥体(結晶性L-カルノシン亜鉛錯体52g、酢酸ナトリウム0.05g)を得た。結果を表4に示す。
原料粗体をリンス洗浄する媒体をメタノールからエタノールに変更した以外は実施例1と同様に行った。結果を表5に示す。
なお、以下では、第一または第二粗体に含まれる揮発分を残存揮発分ともいう。
原料粗体をリンス洗浄する媒体をメタノールからイソプロピルアルコール(以下「IPA」ともいう。)に変更した以外は実施例1と同様に行った。結果を表5に示す。
原料粗体をリンス洗浄する媒体をメタノールから含水メタノール(メタノール:水=60:40(質量比))に変更し、第一粗体の乾燥時間を5時間に変更した以外は実施例1と同様に行った。結果を表5に示す。
原料粗体に添加する媒体をメタノールからエタノールに変更した以外は実施例2と同様に行った。結果を表6に示す。
原料粗体に添加する媒体をメタノールからIPAに変更した以外は実施例2と同様に行った。結果を表6に示す。
原料粗体に添加する媒体をメタノールから含水メタノール(メタノール:水=60:40(質量比))に変更し、第一粗体の乾燥時間を5時間に変更した以外は実施例2と同様に行った。結果を表6に示す。
原料粗体をリンス洗浄する媒体をメタノールから水に変更した以外は実施例1と同様に行った。この際の濾過性は悪く、5時間を必要とした。結果を表7に示す。
原料粗体に添加する媒体をメタノールから水に変更した以外は実施例2と同様に行なった。この際の濾過性は悪く、10時間を必要とした。また、得られた第一粗体は80℃での風乾では乾燥しなかったため、80℃で24時間、減圧乾燥した。結果を表8に示す。
原料粗体206gの代わりに、比較例2で得られた第一粗体(湿体)141.1gを用いた以外は、実施例2と同様にして処理した。得られた第二粗体を80℃で4時間風乾した。なお、この実施例10では、比較例2で得られた第一粗体が本発明における粗体である。結果を表9に示す。
さらに、得られた結晶性L-カルノシン亜鉛錯体は、亜鉛とL-カルノシンとの含有モル比がほぼ1:1で一定であり、洗浄前後において、このモル比はほぼ変化しなかった。
なお、比較例2で得られた乾燥体は、硬く凝集したものであり、この乾燥体を使用するには、乳鉢等で粉砕する必要があったが、実施例1~10で得られた乾燥体は、比較例2の乾燥体よりも容易に粉砕でき、粒度を制御することが容易であった。これは、アルコールを使用することにより、凝集力が弱い(粉砕し易い)乾燥体が得られたためであると考えられる。
以上のことから、本発明に係る製造方法は、より強い抗潰瘍作用を示すなどの医薬品に好適に使用されるL-カルノシン亜鉛錯体を得る方法として、工業的に有利な方法である。
Claims (8)
- 結晶性L-カルノシン亜鉛錯体及びアルカリ金属塩を含有する粗体と炭素数1~3のアルコールを含む液体とを接触させる工程Aを含む、
前記アルカリ金属塩の含有量が低減され、且つ、結晶性L-カルノシン亜鉛錯体を含有する精製体の製造方法。 - 前記精製体中のアルカリ金属塩の含有量が、該精製体の固形分100質量%に対し0.5質量%以下である、請求項1に記載の製造方法。
- 前記精製体中の結晶性L-カルノシン亜鉛錯体における、L-カルノシンと亜鉛とのモル比(L-カルノシンのモル数:亜鉛のモル数)が100:95~105である、請求項1又は2に記載の製造方法。
- 下記式(I)を満たす、請求項3に記載の製造方法。
前記精製体中におけるL-カルノシンに対する亜鉛のモル比/前記粗体中におけるL-カルノシンに対する亜鉛のモル比=0.90~1.10 ・・・(I) - 前記工程Aが、下記工程A1又は工程A2の少なくとも1つを含む、請求項1~4の何れか1項に記載の製造方法。
工程A1:前記粗体を炭素数1~3のアルコールを含む液体に分散させる工程
工程A2:濾過手段内の前記粗体に炭素数1~3のアルコールを含む液体を接触させる工程 - 前記工程Aで用いる粗体中のアルカリ金属塩の含有量が、該粗体の固形分100質量%に対し10質量%以上である、請求項1~5の何れか1項に記載の製造方法。
- 前記炭素数1~3のアルコールが、メタノールである請求項1~6の何れか1項に記載の製造方法。
- 前記粗体が、L-カルノシン、亜鉛化合物及びアルカリ金属化合物をアルコールの存在下で反応させて得られる粗体である、請求項1~7の何れか1項に記載の製造方法。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015561048A JP6457953B2 (ja) | 2014-02-10 | 2015-02-06 | 結晶性l−カルノシン亜鉛錯体を含有する精製体の製造方法 |
CN201580003873.0A CN105899520B (zh) | 2014-02-10 | 2015-02-06 | 含有结晶性l-肌肽锌络合物的纯化物的制造方法 |
KR1020167017114A KR102286357B1 (ko) | 2014-02-10 | 2015-02-06 | 결정성 l-카르노신아연 착체를 함유하는 정제체의 제조 방법 |
HK16111789.4A HK1223623A1 (zh) | 2014-02-10 | 2016-10-12 | 含有結晶性 -肌肽鋅絡合物的純化物的製造方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014-023489 | 2014-02-10 | ||
JP2014023489 | 2014-02-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015119235A1 true WO2015119235A1 (ja) | 2015-08-13 |
Family
ID=53778035
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2015/053354 WO2015119235A1 (ja) | 2014-02-10 | 2015-02-06 | 結晶性l-カルノシン亜鉛錯体を含有する精製体の製造方法 |
Country Status (5)
Country | Link |
---|---|
JP (1) | JP6457953B2 (ja) |
KR (1) | KR102286357B1 (ja) |
CN (1) | CN105899520B (ja) |
HK (1) | HK1223623A1 (ja) |
WO (1) | WO2015119235A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019049824A1 (ja) * | 2017-09-05 | 2019-03-14 | 株式会社トクヤマ | 保護l-カルノシン誘導体、l-カルノシン、および結晶性l-カルノシン亜鉛錯体の製造方法 |
CN114149452A (zh) * | 2021-12-08 | 2022-03-08 | 江苏诚信药业有限公司 | 一种l-肌肽锌络合物的制备方法 |
CN114149452B (zh) * | 2021-12-08 | 2024-11-05 | 江苏诚信药业有限公司 | 一种l-肌肽锌络合物的制备方法 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111196837B (zh) * | 2018-11-20 | 2023-07-28 | 皕达生物科技(上海)有限公司 | 聚普瑞锌的制备方法以及聚普瑞锌制剂 |
KR102191913B1 (ko) | 2019-05-27 | 2020-12-16 | 주식회사 한서켐 | 결정질 폴라프레징크의 제조방법 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07116160B2 (ja) * | 1987-08-10 | 1995-12-13 | 浜理薬品工業株式会社 | 結晶性l−カルノシン亜鉛錯体およびその製造法 |
JP2007204397A (ja) * | 2006-01-31 | 2007-08-16 | Tokuyama Corp | 結晶性l−カルノシン亜鉛錯体の製造方法 |
JP2007246401A (ja) * | 2006-03-13 | 2007-09-27 | Tokuyama Corp | 結晶性l−カルノシン亜鉛錯体の製造方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3294920B2 (ja) | 1993-10-27 | 2002-06-24 | アロカ株式会社 | 超音波画像記録再生装置 |
CN103319413B (zh) * | 2013-06-08 | 2015-02-04 | 西藏海思科药业集团股份有限公司 | 一种聚普瑞锌化合物 |
-
2015
- 2015-02-06 CN CN201580003873.0A patent/CN105899520B/zh active Active
- 2015-02-06 WO PCT/JP2015/053354 patent/WO2015119235A1/ja active Application Filing
- 2015-02-06 JP JP2015561048A patent/JP6457953B2/ja active Active
- 2015-02-06 KR KR1020167017114A patent/KR102286357B1/ko active IP Right Grant
-
2016
- 2016-10-12 HK HK16111789.4A patent/HK1223623A1/zh unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07116160B2 (ja) * | 1987-08-10 | 1995-12-13 | 浜理薬品工業株式会社 | 結晶性l−カルノシン亜鉛錯体およびその製造法 |
JP2007204397A (ja) * | 2006-01-31 | 2007-08-16 | Tokuyama Corp | 結晶性l−カルノシン亜鉛錯体の製造方法 |
JP2007246401A (ja) * | 2006-03-13 | 2007-09-27 | Tokuyama Corp | 結晶性l−カルノシン亜鉛錯体の製造方法 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019049824A1 (ja) * | 2017-09-05 | 2019-03-14 | 株式会社トクヤマ | 保護l-カルノシン誘導体、l-カルノシン、および結晶性l-カルノシン亜鉛錯体の製造方法 |
KR20200050946A (ko) | 2017-09-05 | 2020-05-12 | 가부시끼가이샤 도꾸야마 | 보호 l-카르노신 유도체, l-카르노신, 및 결정성 l-카르노신 아연착체의 제조 방법 |
CN114149452A (zh) * | 2021-12-08 | 2022-03-08 | 江苏诚信药业有限公司 | 一种l-肌肽锌络合物的制备方法 |
CN114149452B (zh) * | 2021-12-08 | 2024-11-05 | 江苏诚信药业有限公司 | 一种l-肌肽锌络合物的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN105899520B (zh) | 2018-07-10 |
KR20160119058A (ko) | 2016-10-12 |
JP6457953B2 (ja) | 2019-01-23 |
KR102286357B1 (ko) | 2021-08-05 |
HK1223623A1 (zh) | 2017-08-04 |
JPWO2015119235A1 (ja) | 2017-03-30 |
CN105899520A (zh) | 2016-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6457953B2 (ja) | 結晶性l−カルノシン亜鉛錯体を含有する精製体の製造方法 | |
JP4619428B2 (ja) | 酸化ビスマス粉の製造方法 | |
JP4936737B2 (ja) | 結晶性l−カルノシン亜鉛錯体の製造方法 | |
KR20160088097A (ko) | 산화 그래핀의 정제방법 | |
JP4540568B2 (ja) | L−カルノシンの製造方法 | |
TWI695009B (zh) | 6,6'-[[3,3',5,5'-肆(1,1-二甲基乙基)-[1,1'-聯二苯]-2,2'-二基]雙(氧基)]雙二苯并[d,f][1,3,2]-二氧雜磷雜庚英之結晶形式 | |
JP3503116B2 (ja) | 高濃度フリーヒドロキシルアミン水溶液の製造法 | |
JP4880332B2 (ja) | 結晶性l−カルノシン亜鉛錯体の製造方法 | |
WO2009119395A1 (ja) | 2-アミノ-2-[2-[4-(3-ベンジルオキシフェニルチオ)-2-クロロフェニル]エチル]-1,3-プロパンジオール塩酸塩の結晶化方法 | |
JP2009001506A (ja) | トリヒドロキシベンゾフェノンの製造方法 | |
JP4198952B2 (ja) | メチオニン及びアルカリ金属炭酸水素塩の晶析方法 | |
JP7469360B2 (ja) | 3,5-ジ-ターシャリーブチルサリチル酸の製造方法 | |
JP6983256B2 (ja) | 精製メチオニンの製造方法 | |
CN111032611A (zh) | 柠檬酸铁水合物的制造方法 | |
JPH0725603A (ja) | 窒化ケイ素粉末の精製方法 | |
JP3001097B1 (ja) | ソルビン酸の製造法 | |
JP6977357B2 (ja) | チオフェンスルホン酸塩 | |
CN105646542A (zh) | 微波法合成硫酸头孢匹罗的方法 | |
JPH11310413A (ja) | 高純度炭酸リチウムの製造方法 | |
AU2002223449B2 (en) | Method for isolating pharmaceutically exploitable etidronate disodium | |
JP5448588B2 (ja) | L−カルノシンの精製方法 | |
JP2590206B2 (ja) | 8−ヒドロキシキノリン−7−カルボン酸の製造方法 | |
EP3656761A1 (en) | Method for producing purified methionine and method for preventing caking of methionine | |
JP5042605B2 (ja) | トリス[トリス(ジメチルアミノ)ホスホラニリデンアミノ]ホスフィンオキシドの製造方法 | |
JPS6016820A (ja) | 微粉状方安鉱の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15746717 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 20167017114 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2015561048 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 15746717 Country of ref document: EP Kind code of ref document: A1 |